Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute‐Comprehensive Cancer Center

Mallen Adrianne R.; Conley Claire C.; Townsend Mary K.; Wells Ali; Boac Bernadette M.; Todd Sarah; Gandhi Anjalika; Kuznicki Michelle; Augusto Bianca M.; McIntyre McKenzie; Fridley Brooke L.; Tworoger Shelley S.; Wenham Robert M.; Vadaparampil Susan T.

首页> 外文期刊>Clinical Genetics: An International Journal of Genetics in Medicine >Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute‐Comprehensive Cancer Center

【24h】

Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute‐Comprehensive Cancer Center

机译：国家癌症学院综合癌症中心卵巢癌患者遗传转介的模式和预测

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Abstract Germline mutations (eg, BRCA1 / 2 ) have prognostic and treatment implications for ovarian cancer (OVCA) patients. Thus, national guidelines recommend genetic testing for OVCA patients. The present study examines patterns and predictors of genetics referral in OVCA patients. Electronic medical record data were abstracted retrospectively from 557 OVCA patients treated from 1 January 2001 to 31 December 2015. Logistic regression models identified sociodemographic characteristics, disease/treatment characteristics, family history data, provider characteristics, and survival data that predicted genetics referral. Overall, 27.5% of patients received referral. Eleven variables predicting referral were selected during stepwise regression: younger age, White race, not having private insurance, professional school education, year of OVCA diagnosis, platinum sensitivity, female gynecologic oncologist, chemotherapy administered by a gynecologic oncologist, clinical trial enrollment, longer overall survival, and family history of OVCA. Genetics referral among OVCA patients was similar to rates reported nationwide. Unique predictive factors will contribute to quality improvement and should be validated at a multi‐institutional level to ensure guideline concordant care is provided to all OVCA patients. Future research should identify both patient‐level and provider‐level factors associated with genetics referral.

机译：摘要种系突变（例如，BRCA1 / 2）对卵巢癌（OVCA）患者具有预后和治疗影响。因此，国家指南推荐对OVCA患者的遗传检测。本研究审查了OVCA患者遗传转诊的模式和预测。从2001年1月1日至2015年12月31日期间的557名患者批评了电子医疗记录数据。逻辑回归模型确定了预测遗传转诊的社会造型特征，疾病/治疗特征，家族史数据，提供者特征和生存数据。总体而言，27.5％的患者接受过转诊。在逐步回归中选择了11个变量：年轻的年龄，白种族，没有私人保险，专业学校教育，ovca诊断年，铂敏感性，雌性妇科肿瘤学家，由妇科肿瘤学家给药，临床试验入学，较长求生存和ovca的家族史。 OVCA患者的遗传转诊与全国报告的率类似。独特的预测因素将有助于质量改进，应在多机构层面验证，以确保向所有OVCA患者提供指南协调性护理。未来的研究应确定与遗传转诊相关的患者水平和提供者级别因素。

著录项

来源
《Clinical Genetics: An International Journal of Genetics in Medicine》 |2020年第2期|共6页
作者
Mallen Adrianne R.; Conley Claire C.; Townsend Mary K.; Wells Ali; Boac Bernadette M.; Todd Sarah; Gandhi Anjalika; Kuznicki Michelle; Augusto Bianca M.; McIntyre McKenzie; Fridley Brooke L.; Tworoger Shelley S.; Wenham Robert M.; Vadaparampil Susan T.;
展开▼
作者单位

Department of Gynecologic OncologyMoffitt Cancer CenterTampa Florida;

Department of Health Outcomes and BehaviorMoffitt Cancer CenterTampa Florida;

Department of Cancer EpidemiologyMoffitt Cancer CenterTampa Florida;

University of South Florida Morsani School of MedicineTampa Florida;

Department of PathologyUniversity of South Florida &

Moffitt Cancer CenterTampa Florida;

Department of Gynecologic OncologyMoffitt Cancer CenterTampa Florida;

Department of Obstetrics and GynecologyUniversity of South FloridaTampa Florida;

Department of Obstetrics and GynecologyUniversity of South FloridaTampa Florida;

Department of Health Outcomes and BehaviorMoffitt Cancer CenterTampa Florida;

Department of Health Outcomes and BehaviorMoffitt Cancer CenterTampa Florida;

Department of Biostatistics and BioinformaticsMoffitt Cancer CenterTampa Florida;

Department of Cancer EpidemiologyMoffitt Cancer CenterTampa Florida;

Department of Gynecologic OncologyMoffitt Cancer CenterTampa Florida;

Department of Health Outcomes and BehaviorMoffitt Cancer CenterTampa Florida;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学遗传学;
关键词
BRCA1/2; genetic counseling; genetic testing; germline mutation; ovarian cancer;

机译：BRCA1 / 2;遗传咨询;基因检测;种系突变;卵巢癌;

相似文献

外文文献
中文文献
专利

1. Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute‐Comprehensive Cancer Center [J] . Mallen Adrianne R., Conley Claire C., Townsend Mary K., Clinical Genetics: An International Journal of Genetics in Medicine . 2020,第2期

机译：国家癌症学院综合癌症中心卵巢癌患者遗传转介的模式和预测
2. Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center [J] . Adam C. ElNaggar, Erinn M. Hade, David M. OMalley, Gynecologic Oncology: An International Journal . 2018,第3期

机译：卵巢癌中化疗的时间：在国家癌症学院指定的综合癌症中心遵守卵巢癌质量指标
3. Impact of National Cancer Institute Comprehensive Cancer Centers on Ovarian Cancer Treatment and Survival [J] . Bristow Robert E., Chang Jenny, Ziogas Argyrios, Journal of the American College of Surgeons . 2015,第5期

机译：美国国家癌症研究所综合癌症中心对卵巢癌治疗和生存的影响
4. Advancing Convergence and Innovation in Cancer Research: National Cancer Institute Center for Strategic Scientific Initiatives (CSSI) [C] . Sarah G. Elder, Jerry S. H. Lee Meeting of the Electrochemical Society . 2017

机译：推进癌症研究的收敛与创新：国家癌症研究所战略科学倡议中心（CSSI）
5. Environmental sustainability and the human element: Decision making in National Cancer Institute-designated cancer centers and Practice Greenhealth subscribing institutions. [D] . Gamble, John H. 2010

机译：环境的可持续性和人为因素：在美国国家癌症研究所指定的癌症中心和实践绿色健康订购机构中进行决策。
6. Impact of National Cancer Institute Comprehensive Cancer Centers on Ovarian Cancer Treatment and Survival [O] . Robert E Bristow, Jenny Chang, Argyrios Ziogas, -1

机译：美国国家癌症研究所综合癌症中心对卵巢癌治疗和生存的影响
7. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-Cell Non-Hodgkin’s lymphoma1,2 1Expert panel members and authors of the review are: Theresa Hahn, PhD, Roswell Park Cancer Institute, Buffalo, NY; Steven N. Wolff, MD, Vanderbilt University, Nashville, TN, Myron Czuczman, MD, Roswell Park Cancer Institute, Buffalo, NY; Richard I. Fisher, MD, Cardinal Bernardin Cancer Center, Loyola University, Chicago, IL; Hillard M. Lazarus, MD, Comprehensive Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH; Philip L. McCarthy, MD, Roswell Park Cancer Institute, Buffalo, NY; Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE; Lisa Warren, Cure for Lymphoma Foundation, New York, NY; and Richard Watt, MD, United Resource Networks, Minneapolis, MN. 2Reference: Hahn T, Wolff SN, Czuczman M, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin’s lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2001;7:308–331. [O] . 2003

机译：造血干细胞移植的细胞毒性治疗在治疗弥漫性大细胞B细胞非霍奇金淋巴瘤1,2中的作用1，专家小组成员和评价的作者是：纽约州布法罗罗斯威尔公园癌症研究所的特蕾莎·哈恩博士；田纳西州纳什维尔范德比尔特大学医学博士斯蒂芬·沃尔夫（Steven N. Wolff），纽约州布法罗罗斯维尔公园癌症研究所医学博士迈伦·库兹曼（Myron Czuczman）；理查德·费舍尔（Richard I. Fisher）医学博士，伊利诺伊州芝加哥洛约拉大学贝纳尔丁枢机主教癌症中心；俄亥俄州克利夫兰凯斯西储大学克利夫兰大学医院综合癌症中心医学博士Hillard M. Lazarus；纽约州布法罗罗斯韦尔公园癌症研究所医学博士Philip L.内布拉斯加州奥马哈市内布拉斯加大学医学中心医学博士Julie Vose；丽莎·沃伦（Lisa Warren），纽约州纽约市淋巴瘤基金会的治疗；和明尼苏达州明尼阿波利斯市联合资源网络公司的医学博士Richard Watt。 2参考文献：Hahn T，Wolff SN，Czuczman M等。一项基于证据的综述：造血干细胞移植的细胞毒性治疗在弥漫性大细胞B细胞非霍奇金淋巴瘤治疗中的作用。 Biol骨髓移植。 2001; 7：308-331。

Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute‐Comprehensive Cancer Center

摘要

著录项

相似文献

相关主题

期刊订阅